Scarica l'app Stockscreener
33.44
4.76%
-1.66
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
(KYMR) Technical Pivots with Risk Controls - Stock Traders Daily
Why Kymera Therapeutics’ Stock is Making Waves - TipRanks
Kymera at TD Cowen Conference: Focus on Clinical Advancements By Investing.com - Investing.com UK
Don't Ignore The Insider Selling In Kymera Therapeutics - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook - Yahoo Finance
What is B. Riley’s Forecast for KYMR FY2025 Earnings? - Defense World
A Guide To The Risks Of Investing In Kymera Therapeutics Inc (KYMR) - Knox Daily
New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
Equities Analysts Offer Predictions for KYMR Q1 Earnings - Defense World
Kymera Therapeutics COO sells $42,113 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief legal officer sells $68,239 in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics CFO sells shares worth $214,219 By Investing.com - Investing.com South Africa
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 By Investing.com - Investing.com Canada
Kymera Therapeutics CFO sells shares worth $214,219 - Investing.com India
Kymera Therapeutics’ chief medical officer sells shares worth $174,785 - Investing.com
Kymera Therapeutics COO sells $42,113 in stock - Investing.com
Kymera Therapeutics announces new performance-based stock plan - Investing.com India
Kymera Therapeutics announces new performance-based stock plan By Investing.com - Investing.com South Africa
Kymera Therapeutics Grants Performance Stock Units to Executives - TipRanks
Rhumbline Advisers Acquires 1,861 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Q3 Earnings Forecast for KYMR Issued By HC Wainwright - Defense World
Analysts Set Expectations for KYMR Q2 Earnings - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat
(KYMR) Trading Signals - Stock Traders Daily
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - TradingView
Kymera Therapeutics Inc (KYMR) Volatility Hits 9.22%: What Good Investors Need To Be Aware Of - Stocks Register
Kymera Therapeutics stock target cut to $54 by H.C. Wainwright - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript - Insider Monkey
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus.com
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews - Benzinga
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate - Yahoo Finance
Kymera Therapeutics misses Q4 estimates, shares dip By Investing.com - Investing.com Australia
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... By GuruFocus - Investing.com Canada
Kymera Therapeutics (NASDAQ:KYMR) Reaches New 52-Week Low After Earnings Miss - Defense World
Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Kymera stock hits 52-week low at $29.23 amid market challenges - Investing.com
Kymera stock hits 52-week low at $29.23 amid market challenges By Investing.com - Investing.com South Africa
Kymera Therapeutics misses Q4 estimates, shares dip - Investing.com India
Kymera Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls -February 27, 2025 at 08:54 am EST - Marketscreener.com
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
KYMERA THERAPEUTICS Earnings Results: $KYMR Reports Quarterly Earnings - Nasdaq
Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Revenue $7.4M, vs. FactSet Est of $14.4M - Marketscreener.com
Kymera Therapeutics, Inc. SEC 10-K Report - TradingView
5.68%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):